ArticleAnnals of surgical oncology2025
Discrepancies in the Reactivity of Mesorectal versus Lateral Lymph Nodes Post-Neoadjuvant Chemoradiotherapy for Rectal Cancer: Insights from Radiological and Pathological Perspectives.
Article in Annals of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
introductionThe heterogeneous treatment response of lateral lymph nodes (LLN) and mesorectal lymph nodes (MLN) to neoadjuvant chemoradiotherapy (NCRT) in locally advanced rectal cancer (LARC) remains poorly understood. This study investigates imaging regression patterns, pathological lymph node regression grade (LRG), and prognostic implications in patients with LARC undergoing radical resection and lateral lymph node dissection (LLND) after NCRT. PATIENTS AND
methodsA total of 110 patients with LARC undergoing radical resection and LLND after NCRT (2018-2024) were enrolled. Visible MLNs and LLNs on initial magnetic resonance imaging (MRI) were matched node-by-node on post-NCRT MRI, and short-axis (SA) diameter regression was calculated. Pathological LRG scores, including LRG-max, LRG-sum, and LRG-ratio, were assessed on the basis of tumor cell proportion and fibrosis. Differences in radiological and pathological regression between MLNs and LLNs were analyzed at lymph node (LN) and patient levels.
resultsMRI assessed 1744 LNs (811 MLNs, 933 LLNs pre-NCRT; 546 MLNs, 969 LLNs post-NCRT). MLNs exhibited higher disappearance rates (32.7% versus 2.4%, P < 0.0001) and greater SA regression (0.596 ± 0.333 versus 0.214 ± 0.242, P < 0.0001) than LLNs. Histopathological re-evaluation of 2108 LNs (916 MLNs, 1192 LLNs) revealed LLNs had higher LRG-max (37.13 versus 21.37, P = 0.011) and LRG-ratio (3.45 ± 1.29 versus 2.47 ± 0.96, P = 0.0003). LRG-sum was an independent prognostic factor for both MLNs and LLNs.
conclusionsLLNs demonstrated lower imaging regression, higher pathological residual cancer, and poorer treatment response compared with MLNs, indicating greater NCRT tolerance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.